NCT01094860 2020-02-11Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid MalignanciesM.D. Anderson Cancer CenterPhase 1 Completed29 enrolled
NCT00406757 2017-11-13Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or LymphomaGlaxoSmithKlinePhase 1 Completed13 enrolled
NCT00006020 2015-03-06S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic LeukemiaSWOG Cancer Research NetworkPhase 2 Completed35 enrolled
NCT00003635 2013-07-18506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating AgentsNational Cancer Institute (NCI)Phase 2 Completed
NCT00003837 2013-06-20506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaNational Cancer Institute (NCI)Phase NA Completed25 enrolled
NCT00003545 2013-02-05506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaNational Cancer Institute (NCI)Phase 2 Completed35 enrolled